Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26803 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Ahmed Ludvigsen Al-Mashhadi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kræftens Bekæmpelse.
Abstract (Originalsprache)
Peripheral T‐Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited‐stage disease is infrequent and not well‐described. This study reports outcomes and prognostic factors in limited‐stage nodal PTCLs in a binational population‐based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited‐stage nodal PTCL (stage I‐II) and treated with CHOP(−like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6–8 cycles of CHOP(−like) therapy and 22% received 3–4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow‐up was 127 months with 5‐years overall survival (OS) of 58% (95% CI: 53–65) and progression‐free survival (PFS) of 53% (95% CI: 47–59). In multivariable analysis, age ≥ 60 years and B‐symptoms were unfavorable and ALK+ anaplastic large cell T‐Cell lymphoma was favorable for survival outcomes. There was no difference in treatment‐specific outcome (3–4 cycles vs. 6–8 cycles of CHOP(−like) ± radiotherapy). Low‐risk patients (age < 60 without B‐symptoms) had a 5‐year OS of 77% (95% CI 67–89%). In the present study of limited‐stage nodal PTCL, survival after curative intent chemotherapy +/− radiotherapy was inferior to that of limited‐stage diffuse large B‐cell lymphoma, but a subgroup of young patients without B‐symptoms had very good outcomes. Treatment outcomes after 3–4 cycles versus 6–8 cycles of CHOP(−like) therapy were comparable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Oncology, Skane University Hospital, Lund, Sweden.
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark.
- Danish Medicines Agency, Copenhagen, Denmark.
ORCID-Profile: Ahmed Ludvigsen Al-Mashhadi, Henrik Cederleuf, Martin Bjerregård Pedersen, Michael Roost Clausen, Peter de Nully Brown, Marianne Tang Severinsen, Fredrik Ellin, Tarec Christoffer El-Galaly
Förderung
- Kræftens Bekæmpelse
Zitieren
APA
Ludvigsen Al-Mashhadi, A., Cederleuf, H., Kuhr Jensen, R., Holm Nielsen, T., Bjerregård Pedersen, M., Bech Mortensen, T., Relander, T., Jerkeman, M., Ortved Gang, A., Kristensen, A. L., Roost Clausen, M., de Nully Brown, P., Tang Severinsen, M., Jakobsen, L. H., Ellin, F., & El-Galaly, T. C. (2023). Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. American Journal of Hematology. https://doi.org/10.1002/ajh.26803
Vancouver
Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerregård Pedersen M, Bech Mortensen T, et al. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. American Journal of Hematology. 2023. doi:10.1002/ajh.26803
BibTeX
@article{LudvigsenAlMashhadi2023,
author = {Ludvigsen Al-Mashhadi, Ahmed and Cederleuf, Henrik and Kuhr Jensen, Rasmus and Holm Nielsen, Torsten and Bjerregård Pedersen, Martin and Bech Mortensen, Thomas and Relander, Thomas and Jerkeman, Mats and Ortved Gang, Anne and Kristensen, Anne Louise and Roost Clausen, Michael and de Nully Brown, Peter and Tang Severinsen, Marianne and Jakobsen, Lasse Hjort and Ellin, Fredrik and El-Galaly, Tarec Christoffer},
title = {Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26803}
}
EUVIMED